Becker's Healthcare January 17, 2025
HHS is investing more than $800 million in vaccine development and manufacturing capacity to strengthen the nation’s response capabilities to emerging infectious disease threats, including bird flu.
Five notes:
- On Jan. 16, the agency said it intends to invest $211 million to support the development of an RNA-based vaccine technology platform and long-term manufacturing capabilities. The funds will be allocated through the agency’s Administration for Strategic Preparedness and Response.
- “The funding will allow us to bring the benefits of mRNA vaccine technology to bear against a wider array of emerging threats,” Dawn O’Connell, assistant secretary for preparedness and response at HHS, said in a Jan. 16 news release. “mRNA technology can be faster to develop and easier...